Ticagrelor Tablet
Product Images NDC 42385-994

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 42385-994). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Laurus Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ticagrelor-figure1 (Ticagrelor Figure1)

A Kaplan-Meier plot showing the cumulative percentage of patients experiencing the first non-CABG PLATO-defined major bleeding event over 360 days from the first study drug dose. The graph compares two groups: Ticagrelor 90 mg (solid line) and Clopidogrel (dashed line). It includes numbers at risk and event counts with percentages for each treatment group at several time points.*

FDA Label Image

Ticagrelor-figure10 (Ticagrelor Figure10)

A line graph titled 'Time to first occurrence of CV death, MI, or stroke (PLATO)' comparing cumulative percentage over days from randomization between Ticagrelor 90 mg and Clopidogrel. The x-axis shows days from 0 to 360, and the y-axis shows cumulative percentage from 0 to 13%. Ticagrelor's curve is solid, while Clopidogrel's curve is dashed, with Clopidogrel showing a higher cumulative percentage of events. A data box presents the number of patients, event percentages, hazard ratio with confidence interval, and p-value, alongside a table of patients at risk at multiple time points for both drugs.*

FDA Label Image

Ticagrelor-figure11 (Ticagrelor Figure11)

A forest plot from subgroup analyses of the PLATO trial comparing Ticagrelor and Clopidogrel across various patient characteristics. The chart displays hazard ratios with 95% confidence intervals for overall treatment effect and subgroups based on geographic region, ASA use, treatment approach, PCI timing, CABG status, diabetes history, prior TIA/stroke, glycoprotein inhibitor use, age, sex, and race. Horizontal bars visualize the comparative risks, with vertical line at 1.0 indicating no difference.*

FDA Label Image

Ticagrelor-figure12 (Ticagrelor Figure12)

A forest plot illustrating cardiovascular death, myocardial infarction, and stroke outcomes based on maintenance aspirin doses (mg) in regions US and Non-US, comparing Ticagrelor and Clopidogrel groups. The chart shows hazard ratios (HR) with 95% confidence intervals, indicating relative effectiveness of Ticagrelor versus Clopidogrel across aspirin dose subgroups.*

FDA Label Image

Ticagrelor-figure13 (Ticagrelor Figure13)

A cumulative percentage line chart titled 'Time to First Occurrence of CV death, MI or Stroke (PEGASUS)' showing three groups: Ticagrelor 90 mg, Ticagrelor 60 mg, and Placebo over days from randomization up to approximately 1320 days. The chart includes the number of patients at risk at various time points and summary statistics such as hazard ratios and confidence intervals for each dose group compared to placebo.*

FDA Label Image

Ticagrelor-figure14 (Ticagrelor Figure14)

A forest plot showing subgroup analyses of ticagrelor 60 mg versus placebo from the PEGASUS study. The chart displays hazard ratios (HR) with 95% confidence intervals across various patient characteristics such as age, sex, race, weight, BMI, geographic region, history of myocardial infarction, diabetes, and others. Ticagrelor generally shows a treatment benefit compared to placebo across most subgroups.*

FDA Label Image

Ticagrelor-figure15 (Ticagrelor Figure15)

A Kaplan-Meier curve showing the time to first occurrence of cardiovascular death, myocardial infarction, or stroke in the THEMIS study. The graph compares Ticagrelor and placebo treatments over 54 months from randomization, depicting cumulative event percentages with patient counts at risk over time.*

FDA Label Image

Ticagrelor-figure16 (Ticagrelor Figure16)

A subgroup analysis forest plot for Ticagrelor from the THEMIS study, showing hazard ratios (HR) and 95% confidence intervals across different patient characteristics. The plot compares Ticagrelor and placebo outcomes, illustrating HR values that indicate relative effectiveness, with groups including age, sex, race, BMI, geographic region, aspirin use, HbA1c, eGFR, insulin use, angina history, coronary artery disease, PCI, CABG, smoking status, and diabetes duration.*

FDA Label Image

Ticagrelor-figure17 (Ticagrelor Figure17)

A Kaplan-Meier plot showing time to first occurrence of stroke or death from the THALES study. The graph compares cumulative percentage over 34 days from randomization between Ticagrelor 90 mg (solid line) and placebo (dashed line). It includes risk table, event counts, and percentages for each group by day 30.*

FDA Label Image

Ticagrelor-figure18 (Ticagrelor Figure18)

A subgroup analysis forest plot chart for ticagrelor 90 mg from the THALES study. The chart compares hazard ratios (HR) with 95% confidence intervals for various patient characteristics, including age, sex, race, weight, geography, and medical history, showing ticagrelor versus placebo outcomes. The horizontal axis ranges from 0.5 (ticagrelor better) to 2 (placebo better).*

FDA Label Image

Ticagrelor-figure19 (Ticagrelor Figure19)

The label for Ticagrelor Tablets 60 mg displays the active ingredient ticagrelor per tablet. It states storage conditions and a warning to keep out of children's reach. The product is manufactured by Laurus Labs Limited, India, and labeled for Laurus Generics Inc., USA. The package contains 30 tablets for oral use, with an NDC ending in 993-30.*

FDA Label Image

Ticagrelor-figure2 (Ticagrelor Figure2)

A bar chart titled 'Major fatal/life-threatening CABG-related bleeding by days from last dose of study drug to CABG procedure (PLATO)'. The y-axis shows the percentage of patients who had an event following CABG, ranging from 0 to 100%. The x-axis represents days from last dose to CABG procedure, from 1 to 8 or more. Data is shown in paired bars for two groups labeled T and C on each day with event counts listed below. The chart visualizes bleeding event rates by day for groups T and C.*

FDA Label Image

Ticagrelor-figure20 (Ticagrelor Figure20)

A set of identical printed labels for Ticagrelor Tablet 60 mg in a sheet layout. Each label includes 'Rx only,' the NDC number 42385-993-17, the product name Ticagrelor Tablet with strength 60 mg in a purple box, manufacturing information by Laurus Labs Limited, and barcode. Spaces for lot number and expiration date are blank.*

FDA Label Image

Ticagrelor-figure21 (Ticagrelor Figure21)

The image shows the packaging label for Ticagrelor Tablets 60 mg, manufactured by Laurus Labs Limited. The label indicates the product is for institutional use only and contains 100 unit-dose tablets (10 x 10). Storage instructions and warnings about keeping out of reach of children are included. The label displays both the Laurus Labs and Laurus Generics Inc. manufacturer information and a barcode.*

FDA Label Image

Ticagrelor-figure22 (Ticagrelor Figure22)

Ticagrelor 90 mg tablets label for oral administration by Laurus Labs Limited. The label states each tablet contains 90 mg of ticagrelor and instructs to dispense the accompanying Medication Guide. The package contains 30 tablets and is labeled for prescription use only. Storage instructions specify 20° to 25°C with permitted excursions. Manufactured for Laurus Generics Inc., India.*

FDA Label Image

Ticagrelor-figure23 (Ticagrelor Figure23)

Label sheet containing multiple identical labels for Ticagrelor Tablet 90 mg, an oral prescription drug manufactured by Laurus Labs Limited. Each label includes the product name, strength, manufacturer, barcode, National Drug Code (NDC 42385-994-17), and fields for lot and expiration information.*

FDA Label Image

Ticagrelor-figure24 (Ticagrelor Figure24)

Ticagrelor Tablets 90 mg oral tablet packaging label shows the product name, strength, and dosage form. It is labeled for institution use only, with a unit-dose package containing 100 tablets (10 x 10). The label includes storage instructions, warnings, manufacturer information (Laurus Labs Limited), and a barcode. The brand Laurus Labs is displayed.*

FDA Label Image

Figure25 (Ticagrelor Figure25)

Ticagrelor 90 mg tablet packaging label. The image shows a white and green blister card containing round tablets. The label includes the product name Ticagrelor, strength 90 mg, and manufacturer Laurus Labs Limited. The packaging is intended for oral administration.*

FDA Label Image

Ticagrelor-figure3 (Ticagrelor Figure3)

A line graph depicting the cumulative percentage of patients experiencing the first TIMI major bleeding event over months from randomization in a clinical study (THEMIS). Two lines compare Ticagrelor (solid line) and Placebo (dashed line), with Ticagrelor showing a higher cumulative percentage over time. The x-axis represents months from randomization (0 to 54), and the y-axis shows cumulative percentage (0% to 7%). Patient numbers at risk at various time points are noted below the graph.*

FDA Label Image

Ticagrelor-figure4 (Ticagrelor Figure4)

A line graph titled 'Time course of GUSTO severe bleeding events' comparing cumulative percentage over days from randomization between Ticagrelor 90 mg twice daily and placebo. The graph shows two lines, one solid for Ticagrelor and one dashed for placebo, with data points indicating events and risk numbers at various time intervals.*

FDA Label Image

Ticagrelor-figure5 (Ticagrelor Figure5)

A line graph showing mean inhibition of platelet aggregation (IPA %) over time (hours) after single oral doses of placebo, 180 mg ticagrelor, and 600 mg clopidogrel. The graph depicts time on the x-axis and IPA percentage on the y-axis, with ticagrelor reaching a higher and sustained inhibition compared to clopidogrel and placebo.*

FDA Label Image

Ticagrelor-figure6 (Ticagrelor Figure6)

A line graph illustrating mean inhibition of platelet aggregation (IPA) over 10 days following 6 weeks of treatment with placebo, ticagrelor 90 mg twice daily, or clopidogrel 75 mg daily. Ticagrelor shows the highest IPA initially, decreasing over time, followed by clopidogrel and placebo with minimal change. An inset graph displays IPA percentage over 48 hours.*

FDA Label Image

Ticagrelor-figure7 (Ticagrelor Figure7)

A chart titled 'Mean effect and 90% CI' comparing Ticagrelor and AR-C124910XX across various intrinsic factors such as age, gender, ethnicity, renal impairment, end-stage renal disease on hemodialysis, and mild hepatic impairment. The chart shows changes relative to reference for Cmax and AUC with no dose adjustments recommended for any factor.*

FDA Label Image

Ticagrelor-figure8 (Ticagrelor Figure8)

A comparative figure showing the mean effect and 90% confidence interval of Ticagrelor and AR-C124910XX when administered with various interacting drugs. The horizontal axis represents change relative to reference, with symbols indicating pharmacokinetic measures (Cmax as squares and AUC as triangles). The chart includes recommendations for each interacting drug, such as 'Avoid concomitant use' or 'No dose adjustment.'*

FDA Label Image

Ticagrelor-figure9 (Ticagrelor Figure9)

A forest plot showing the pharmacokinetic interaction effects of Ticagrelor doses on various interacting drugs, including Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, Cyclosporin, and Rosuvastatin. The chart displays mean effect and 90% confidence intervals for changes in CMAX, AUC, and PK with corresponding dosage notes and recommendations for dose adjustments or references to sections for further details.*

FDA Label Image

Ticagrelor-structure (Ticagrelor Structure)

Chemical structure of the active ingredient ticagrelor, showing its molecular framework including a triazolopyrimidine core, a cyclopropyl group, and hydroxylated sugar moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.